CDK9-IN-2 是一种特异性CDK9抑制剂，详细信息请参考专利 WO/2012131594A1 中的化合物 CDKI(8)。它在 A2058 皮肤细胞系（72 小时）和 H929 多发性骨髓瘤细胞系（72小时）的IC50分别为 7 nM 和 5 nM。

CDK9-IN-2 is a special CDK9 inhibitor extracted from patent WO/2012131594A1 (compound CDKI(8)) and has an IC50 of 5 nM and 7 nM in A2058 skin cell line (72 hours) and H929 multiple myeloma cell line (72 hours), respectively.

CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment, and it is further reduced after 16-hour exposure to CDK9-IN-2 (500 nM).

1263369-28-3

C23H25ClFN5

425.93

N2'-(反式-4-氨基环己基)-5'-氯-N6-[(3-氟苯基)甲基]-[2,4'-联吡啶]-2',6-二胺

DMSO:50 mg/mL (117.39 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years